A genomic and proteomic study of the spectrum of nonalcoholic fatty liver disease

被引:182
作者
Younossi, ZM
Baranova, A
Ziegler, K
Del Giacco, L
Schlauch, K
Born, TL
Elariny, H
Gorreta, F
VanMeter, A
Younoszai, A
Ong, JP
Goodman, Z
Chandhoke, V
机构
[1] Inova Fairfax Hosp, Ctr Liver Dis, Falls Church, VA 22042 USA
[2] George Mason Univ, Ctr Study Genom Liver Dis, Manassas, VA USA
[3] Armed Forces Inst Pathol, Washington, DC 20306 USA
关键词
D O I
10.1002/hep.20838
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Nonalcoholic fatty liver disease (NAFLD) is the most common chronic liver disease, and some of its forms are progressive. This study describes the profiling of hepatic gene expression and serum protein content in patients with different subtypes of NAFLD. Liver biopsy specimens from 98 bariatric surgery patients were classified as normal, steatosis alone, steatosis with nonspecific inflammation, and nonalcoholic steatohepatitis (NASH). Microarray hybridizations were performed in triplicate and the microarray expression levels of a selected group of genes were confirmed using real-time quantitative reverse-transcriptase polymerase chain reaction. Serum protein profiles of the same patients were determined by SELDI-TOF mass spectrometry. Of 98 obese patients, 91 were diagnosed with NAFLD (12 steatosis alone, 52 steatosis with nonspecific inflammation, and 27 NASH), and 7 patients without NAFLD served as obese controls. Each group of NAFLD patients was compared with the obese controls, and 22 genes with more than twofold differences in expression levels were revealed. Proteomics analyses were performed for the same group comparisons and revealed twelve significantly different protein peaks. In conclusion, this genomic/proteomic analysis suggests differential expression of several genes and protein peaks in patients within and across the forms of NAFLD. These findings may help clarify the pathogenesis of NAFLD and identify potential targets for therapeutic intervention.
引用
收藏
页码:665 / 674
页数:10
相关论文
共 50 条
[1]   Independent predictors of liver fibrosis in patients with nonalcoholic steatohepatitis [J].
Angulo, P ;
Keach, JC ;
Batts, KP ;
Lindor, KD .
HEPATOLOGY, 1999, 30 (06) :1356-1362
[2]   Treatment of nonalcoholic fatty liver: Present and emerging therapies [J].
Angulo, P ;
Lindor, KD .
SEMINARS IN LIVER DISEASE, 2001, 21 (01) :81-88
[3]   NONALCOHOLIC STEATOHEPATITIS - AN EXPANDED CLINICAL ENTITY [J].
BACON, BR ;
FARAHVASH, MJ ;
JANNEY, CG ;
NEUSCHWANDERTETRI, BA .
GASTROENTEROLOGY, 1994, 107 (04) :1103-1109
[4]   Insulin resistance in obesity: Metabolic mechanisms and measurement methods [J].
Belfiore, F ;
Iannello, S .
MOLECULAR GENETICS AND METABOLISM, 1998, 65 (02) :121-128
[5]   CONTROLLING THE FALSE DISCOVERY RATE - A PRACTICAL AND POWERFUL APPROACH TO MULTIPLE TESTING [J].
BENJAMINI, Y ;
HOCHBERG, Y .
JOURNAL OF THE ROYAL STATISTICAL SOCIETY SERIES B-STATISTICAL METHODOLOGY, 1995, 57 (01) :289-300
[6]   Expanding the natural history from cryptogenic cirrhosis to of nonalcoholic steatohepatitis: Hepatocellular carcinoma [J].
Bugianesi, E ;
Leone, N ;
Vanni, E ;
Marchesini, G ;
Brunello, F ;
Carucci, P ;
Musso, A ;
De Paolis, P ;
Capussotti, L ;
Salizzoni, M ;
Rizzetto, M .
GASTROENTEROLOGY, 2002, 123 (01) :134-140
[7]   Cryptogenic cirrhosis: Clinical characterization and risk factors for underlying disease [J].
Caldwell, SH ;
Oelsner, DH ;
Iezzoni, JC ;
Hespenheide, EE ;
Battle, EH ;
Driscoll, CJ .
HEPATOLOGY, 1999, 29 (03) :664-669
[8]   An ab initio study of di- and trifluorobenzene-benzene complexes as relevant to carbonic anhydrase II-drug interactions [J].
Chandra, PP ;
Jain, A ;
Sapse, AM .
JOURNAL OF MOLECULAR MODELING, 2004, 10 (01) :1-5
[9]   Etiopathogenesis of nonalcoholic steatohepatitis [J].
Chitturi, S ;
Farrell, GC .
SEMINARS IN LIVER DISEASE, 2001, 21 (01) :27-41
[10]   Genetics moves into the medical mainstream [J].
Collins, FS ;
Guttmacher, AE .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2001, 286 (18) :2322-2324